Evidence map›Paper›PMID 39354271›Full record

SynthesisDigestive diseases and sciences2024

Comparison of TC-325 Hemostatic Powder with Standard Endoscopic Treatments for Malignancy-Related Upper Gastrointestinal Bleeding: Meta-Analysis of Randomized Controlled Trials.

Aamir Saeed, Saira Yousuf, Muhammad Hashim Hayat, Marjan Haider, Muhammad Aziz, Umar Hayat, Christian Salcedo, Zahid Ijaz Tarar, Umer Farooq, Sachit Sharma and 2 more

Abstract readMeta-AnalysisComparative Study
PubMed Publisher
In one paragraph

Synthesis in Digestive diseases and sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Aamir SaeedDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Saira YousufDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Muhammad Hashim HayatDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Marjan HaiderDepartment of Gastroenterology, Trinity Health Ann Arbor, Ypsilanti, MI, USA.
Muhammad AzizDivision of Gastroenterology, Bon Secours Mercy Health, Toledo, OH, USA.
Umar HayatDivision of Gastroenterology, Geisinger Wyoming Valley Medical Centre, Wilkes-Barre, PA, USA.
Christian SalcedoDepartment of Medicine, University of Tennessee Health Science Center, Memphis, TN, USA.
Zahid Ijaz TararDepartment of Gastroenterology, University of Missouri-Columbia, Columbia, MO, USA.
Umer FarooqDivision of Gastroenterology, St Louis University School of Medicine, St Loius, MO, USA.
Sachit SharmaDivision of Gastroenterology, Virginia Commonwealth University, Richmond, VA, USA.
Muhammad Ali KhanDepartment of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Faisal KamalDivision of Gastroenterology, Thomas Jefferson University Hospital, 132 South 10th Street, Main Building, Suite 480, Philadelphia, PA, 19107, USA. fkamal36@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTC-325 powder has been successfully used in the management of malignancy-related upper gastrointestinal bleeding (UGIB) with favorable results. We conducted a meta-analysis of randomized controlled trials (RCTs) comparing TC-325 hemostatic powder with standard endoscopic treatments in the management of malignancy-related UGIB.

methodsSeveral databases were reviewed from inception to May 02, 2024 to identify RCTs comparing TC-325 and standard endoscopic treatments for the management of malignancy-related UGIB. Our outcomes of interest were immediate hemostasis, 30-day rebleeding, length of hospital stay, need for surgery, need for angiographic embolization, and all-cause mortality. We calculated pooled risk ratio (RR) with 95% confidence intervals (CI) for categorical variables and mean difference (MD) with 95% CI for continuous variables. We used a random effect model to analyze the data and heterogeneity was assessed by I

resultsFour RCTs with 227 patients were included. We found that, the rate of immediate hemostasis was significantly higher in the TC-325 group compared to the standard therapy group, RR (95% CI): 1.48 (1.26, 1.74). There was no significant difference in 30-day rebleeding between the groups RR (95% CI): 0.52 (0.15, 1.76). We found no significant difference in other outcomes between groups such as the need for angiographic embolization, all-cause mortality, length of hospital stay, and need for surgery.

conclusionsWe found that, TC-325 hemostatic powder was superior to standard endoscopic treatments in achieving immediate hemostasis in patients with malignancy-related UGIB.

Indexed as

Gastrointestinal HemorrhageHemostasis, EndoscopicHemostaticsPowdersGastrointestinal NeoplasmsHumansMineralsRandomized Controlled Trials as TopicTreatment OutcomehemosprayHemostaticsMineralsPowdersEndoscopyImmediate hemostasisMalignancyStandard therapyTC-325 hemosprayUpper gastrointestinal bleeding

Identifiers

PMID39354271

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.